Cholecystitis Clinical Trial
Official title:
Variation in Cholecystitis Treatment and Outcome in the Netherlands; a Nation-wide Cohort Study
Background: Cholecystitis is treated by in various types of hospitals by different specialists, and treatment strategy is influenced by logistical and medical reasons and personal preference. This may significantly impact hospital stay and other outcomes. Purpose: To determine the variation in treatment of cholecystitis in the Netherlands and its impact on outcome. Methods: Nation-wide cohort study of all patients diagnosed and treated for cholecystitis during a 6 month period. The primary outcome will be the proportion of patients with an acute cholecystitis in which the guideline is followed. This group will be compared to those in which the guideline is not followed, focussing on total hospital stay and complications. Secondary aims are to determine: factors related to guideline compliance; the best method of cystic duct closure; the best treatment strategy for a >7-day existing cholecystitis; factors predictive for concomitant common bile duct stones; strategies following gallbladder drainage. Multivariable analysis and propensity score matching will be used when appropriate for the etiological study aims. The TRIPOD guideline for prediction modelling will be used for the predictive study aims. Hospitals will receive their own results, set out against the national average and best practices, thereafter subsequent changes in hospital practice will be recorded. Conclusion: This study will determine the variation in treatment of cholecystitis in the Netherlands and its impact on clinical outcome. Its results will serve as an important incentive to create optimal, uniform cholecystitis treatment in the Netherlands.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT03636841 -
Reduction of Operating Time by a Smoke Electroprecipitation Device for Acute Cholecystitis
|
N/A | |
| Completed |
NCT02379780 -
Ultrasound Guided Subcostal Transversus Abdominis Plane Versus Paravertebral Block in the Laparoscopic Cholecystectomy
|
N/A | |
| Completed |
NCT02461147 -
Prospective Validation of "Cholecystectomy First" Strategy for Gallstone Migration
|
||
| Completed |
NCT02264444 -
Establishing Visualization Grading Scale on LESS Cholecystectomy
|
N/A | |
| Completed |
NCT01937104 -
ONSD According to the Position During Laparoscopy
|
N/A | |
| Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
| Completed |
NCT00940264 -
Laparoscopic Transvaginal Hybrid Cholecystectomy: a Prospective Data Collection.
|
N/A | |
| Completed |
NCT00746850 -
Harmonic in Laparoscopic Cholecystectomy for Acute Cholecystitis
|
N/A | |
| Completed |
NCT00370344 -
Small-incision Open Cholecystectomy or Laparoscopic Cholecystectomy for Gallbladder Disease
|
Phase 2/Phase 3 | |
| Completed |
NCT00195351 -
Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection
|
Phase 4 | |
| Completed |
NCT02858986 -
3D Versus 4K Laparoscopic Cholecystectomy
|
N/A | |
| Completed |
NCT04602156 -
US-guided Trocar Versus Seldiger Technique for Percutaneous Cholecystostomy
|
N/A | |
| Completed |
NCT04942665 -
Low Dose ICG for Biliary Tract and Tumor Imaging
|
Phase 2 | |
| Completed |
NCT02547064 -
Effect of Modified Stylet Angulation on the Intubation With GlideScope®
|
N/A | |
| Completed |
NCT00230971 -
Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI)
|
Phase 4 | |
| Completed |
NCT04122261 -
A Clinical Study of Chinese Domestic Surgical Robot
|
N/A | |
| Completed |
NCT04716166 -
Incentive Spirometry and Upper Abdominal Laparoscopic Surgery
|
N/A | |
| Completed |
NCT01476319 -
Improving Informed Consent Process for Percutaneous Cholecystostomy in the Emergency Department
|
N/A | |
| Withdrawn |
NCT02225418 -
Transmuscular Quadratus Lumborum Block for Laparoscopic Cholecystectomy
|
N/A | |
| Suspended |
NCT04306939 -
Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study
|